ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1341

Impact of Ultrasound on Physician Assessments of Patients with RA with Elevated Clinical Disease Activity Scores

Stephanie Song1, Odette Kolenky1, Antje Greenfield2, Dana Direnzo3, Joshua Baker4 and Michael George4, 1Hospital of the University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania Health System, Philadelphia, PA, 3University of Pennsylvania, Bala Cynwyd, PA, 4University of Pennsylvania, Philadelphia, PA

Meeting: ACR Convergence 2023

Keywords: Disease Activity, rheumatoid arthritis, Ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1308–1344) RA – Treatments Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Treat-to-target is recommended in RA, but physicians often do not escalate therapy despite elevated disease activity measures due to uncertainty regarding the true degree of joint inflammation. This study evaluated the utility of ultrasound (U/S) in assessing disease activity in patients with RA with moderate disease activity measures but few swollen joints. We aimed to determine the frequency of active synovitis on U/S and compare physician treatment recommendations before and after U/S.

Methods: This single-center, prospective study enrolled adults who met 2010 ACR classification criteria for RA, had a clinical disease activity index (CDAI) >10 (moderate or high disease activity) but a swollen joint count (SJC) ≤2, and were receiving a DMARD. Patients completed surveys and underwent standardized U/S performed in the musculoskeletal (MSK) ultrasound department by a certified MSK U/S technologist using a high-resolution GE Logiq E10 system. Exams were interpreted by a single MSK U/S radiologist using the validated OMERACT scoring system, grading synovial hypertrophy by grayscale (GS) and hyperemia by power doppler (PD) in each of the bilateral MCPs, PIPs, and wrists as absent (0), minimal (1), moderate (2), or severe (3). Treating rheumatologists were surveyed pre-U/S and again after U/S to capture their impression of disease activity, confidence in their assessment (100-point scale), and treatment recommendations.

Results: We recruited 18 patients with RA: 15 (83%) females, mean age 62 years, and mean RA duration 14 years. U/S revealed moderate or severe synovial hypertrophy (GS grade 2 or 3) of at least one joint in 17/18 (94%) patients. In contrast, moderate or severe hyperemia of at least one joint (PD grade 2 or 3) was found in 7/18 (39%). Patients with active PD signal tended to be older, have longer disease duration, more frequent glucocorticoid use, higher body mass index, and more frequent seropositivity and erosions on radiographs; patient and physician global scores and PROMIS measures were similar (Table 1). Although CDAI scores indicated at least moderate disease activity pre-U/S, physician impression was that disease activity was low in 8/18 (44%) of patients pre-U/S. Physician-rated disease activity assessment changed after U/S in 6/18 (33%) patients: 3 to a higher level of disease activity and 3 to a lower level (Figure 1). Similarly, treatment decisions changed after U/S in 6/18 (33%) patients: 3 from no change to escalation of therapy and 3 from escalation to no change (Figure 1). Mean physician confidence in disease activity assessment increased from 54 pre-U/S to 72 post-U/S (p< 0.01).

Conclusion: In patients with longstanding RA, U/S demonstrating a moderate to high degree of synovial hypertrophy in at least one joint was nearly universal, but the presence of active PD signal was less common. Musculoskeletal U/S increased physician confidence in the assessment of disease activity and frequently led to a change in assessment and treatment recommendation. Future research should evaluate whether use of U/S to refine assessments of disease activity in patients with RA with high disease activity scores but few swollen joints can improve patient outcomes.

Supporting image 1

Table 1. Patient Characteristics by Maximum Power Doppler Synovitis Score

Supporting image 2

Figure 1. Pre- and Post-Ultrasound Physician Disease Activity Assessments

Supporting image 3

Figure 2. Pre- and Post-Ultrasound Physician Treatment Recommendations


Disclosures: S. Song: None; O. Kolenky: None; A. Greenfield: None; D. Direnzo: None; J. Baker: Bristol-Myers Squibb(BMS), 2, Burns-White, LLC, 2, CorEvitas, LLC, 2, Pfizer, 2; M. George: AbbVie/Abbott, 2, GlaxoSmithKlein(GSK), 5, Janssen, 5.

To cite this abstract in AMA style:

Song S, Kolenky O, Greenfield A, Direnzo D, Baker J, George M. Impact of Ultrasound on Physician Assessments of Patients with RA with Elevated Clinical Disease Activity Scores [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/impact-of-ultrasound-on-physician-assessments-of-patients-with-ra-with-elevated-clinical-disease-activity-scores/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-ultrasound-on-physician-assessments-of-patients-with-ra-with-elevated-clinical-disease-activity-scores/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology